Medpace (MEDP) Form 4: CEO Troendle reports 620-share sale at $475

Rhea-AI Filing Summary

August J. Troendle, CEO, director and reported 10% owner of Medpace Holdings, Inc. (MEDP) reported a sale of 620 shares of the issuer's common stock on 08/27/2025 at $475 per share executed pursuant to a limit order placed during an open window period. After the sale the reporting person directly beneficially owns 961,995 shares and is reported as indirectly owning 4,733,019 shares through Medpace Investors, LLC, of which he is sole manager and controlling unit holder.

The filing clarifies that Troendle disclaims beneficial ownership of MPI-held shares except to the extent of his pecuniary interest and the Form 4 was signed by an attorney-in-fact on 08/28/2025.

Positive

• Transaction disclosed promptly under Section 16 via Form 4, supporting regulatory transparency
• Sale executed via limit order during open window, as stated in the explanation, which is consistent with orderly trading practices
• Reporting person retains substantial ownership: 961,995 shares directly and 4,733,019 shares indirectly via Medpace Investors, LLC

Negative

• Insider sale occurred—while small in size, some investors may interpret any insider disposition as a negative signal

Insights

Corporate Governance Expert

TL;DR: Insider sale disclosed; ownership concentration remains large and the transaction was executed under a limit order in an open window.

The filing documents a small-scale disposition relative to the reporting person's aggregate holdings, with a reported sale of 620 shares at $475. The report notes indirect ownership via Medpace Investors, LLC with sole managerial and voting control retained by the reporting person, and includes the customary disclaimer limiting claimed beneficial ownership of MPI-held shares. The filing follows Section 16 reporting protocols and was executed by an attorney-in-fact, indicating procedural compliance.

Securities/Financial Analyst

TL;DR: Transaction size is immaterial versus total reported holdings; disclosure maintains market transparency.

From a market-impact perspective, the sale of 620 shares at $475 is negligible compared with the reported direct holding of 961,995 shares and indirect holding of 4,733,019 shares through MPI. The sale was effected via a limit order during an open window, which reduces concerns about opportunistic trading. The filing provides clear quantities and pricing, enabling investors to update insider ownership metrics accurately.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troendle August J.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		S(1)		620	D	$475	961,995	D
Common Stock								4,733,019	I	By Medpace Investors, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did August J. Troendle report on Form 4 for MEDP?

The Form 4 reports a sale of 620 shares of Medpace common stock on 08/27/2025 at a price of $475 per share.

How many Medpace shares does Troendle own after the reported transaction?

Following the transaction Troendle is reported to directly own 961,995 shares and to indirectly own 4,733,019 shares through Medpace Investors, LLC.

What is the nature of the indirect ownership reported?

Troendle is the sole manager and controlling unit holder of Medpace Investors, LLC and has sole voting and investment control over the securities held by MPI, but disclaims beneficial ownership except to the extent of his pecuniary interest.

How was the sale executed according to the Form 4?

The filing states the sale was effected pursuant to a limit order placed by the Reporting Person during an open window period.

Who signed the Form 4 filing?

The Form 4 was signed by Stephen P. Ewald, Attorney-in-Fact for August J. Troendle on 08/28/2025.